Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Daratumumab: a necessary addition to the standard of care for MM?

Katja J. Weisel, MD, from The University Hospital of Tübingen, Tübingen, Germany, evaluates the effectiveness of administering daratumumab, a safe and well-tolerated monoclonal antibody, to the standard regimen of care for treating relapsed or refractory multiple myeloma. She reports that in previous clinical trials, MM patients who had only received one treatment line prior to daratumumab therapy were found to benefit more from treatment (NCT02076009) (NCT02136134), which suggests that daratumumab therapy may be more effective if administered earlier to patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.